Managed Entry Agreements in Latin America
Author Information
Author(s): García Martí Sebastián, Pichon-Riviere Andrés, Augustovski Federico, Espinoza Manuel
Primary Institution: Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)
Hypothesis
How can managed entry agreements contribute to coverage decisions in Latin America?
Conclusion
The Policy Forum highlighted the importance of flexible managed entry agreement implementation to address data uncertainty and promote stakeholder dialogue.
Supporting Evidence
- Interest in managed entry agreements is increasing in Latin America.
- Financial agreements are more prevalent than those based on clinical outcomes.
- Barriers to implementation include lack of legal frameworks and insufficient reliable data.
- Early stakeholder involvement can enhance dialogue and understanding.
Takeaway
This study talks about how agreements can help make new medicines available to more people in Latin America, even when there are uncertainties about their effectiveness.
Methodology
The article is based on a background document, a survey, and discussions from the Policy Forum.
Potential Biases
Potential biases may arise from the diverse interests of stakeholders involved in the discussions.
Limitations
The article does not represent a formal consensus or complete representation of participant perspectives.
Participant Demographics
Participants included representatives from HTA agencies, payers, manufacturers, and patient associations from 11 countries.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website